It is recognized that, while mGluR5 antagonism has robust efficacy in Fmr1 KO mice13, 16, 61, similar pharmacological intervention only shows mild effects in a subpopulation of human FXS patients60. The gene discussed is GRM5; the disease is fragile X syndrome.